HAE

11 registered clinical trials studyying HAE — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) NCT07428499	ADARx Pharmaceuticals, Inc.	Phase 3
Recruiting	STOP-HAE: A Phase 3 Study of ADX-324 in HAE NCT06960213	ADARx Pharmaceuticals, Inc.	Phase 3
Recruiting	Hemorrhoidal Artery Embolization: Longitudinal Impact On Symptoms (HELIOS) NCT07179601	University of California, Los Angeles	N/A
Active Not Recruiting	A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema NCT05121376	BioMarin Pharmaceutical	Phase 1 / Phase 2
Enrolling By Invitation	Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat Studies NCT04933721	BioCryst Pharmaceuticals	Phase 3
Completed	Biomarker for Hereditary AngioEdema Disease NCT03029728	CENTOGENE GmbH Rostock	—
Completed	A Long Term Safety Study of BCX7353 in Hereditary Angioedema NCT03472040	BioCryst Pharmaceuticals	Phase 2 / Phase 3
Completed	Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE NCT03485911	BioCryst Pharmaceuticals	Phase 3
Terminated	Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary Angioedema NCT02670720	BioCryst Pharmaceuticals	Phase 3
Completed	12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE Attacks NCT02303626	BioCryst Pharmaceuticals	Phase 2 / Phase 3
Approved For Marketing	Oral Berotralstat Expanded Access Program NCT04428632	BioCryst Pharmaceuticals	—